Peptides and aging skin: senescence explained

A cell does not have to keep dividing to keep affecting your skin. That is the idea behind research into cellular senescence, a state in which cells stop multiplying but remain biologically active. Some release signals that change how nearby cells behave.

A stopped cell can still send signals

Skin contains several kinds of cells doing different jobs. Fibroblasts help maintain the supporting tissue beneath the surface. Melanocytes produce pigment. Either can acquire features of senescence, but they do not necessarily behave identically once they do.

Senescence is more than a temporary rest from dividing. It involves a lasting growth arrest, often accompanied by changes in the substances a cell releases. Researchers call that mixture the senescence-associated secretory phenotype, or SASP. It can include inflammatory signals, growth factors and enzymes that act on the tissue surrounding cells.

The important idea is communication. A change inside one cell can alter the environment its neighbors live in.

In a human skin study, Ressler and colleagues found more cells containing the senescence-associated protein p16 in older donors than in younger groups, in both the surface layer and the deeper dermis. That connected a laboratory marker with aging in actual human tissue. Ressler et al., Aging Cell

A later study made the neighbor effect tangible. Researchers found that senescent melanocytes could impair the multiplication of nearby keratinocytes, the main cells of the outer skin layer. In reconstructed human epidermis, including senescent melanocytes contributed to a thinner tissue. This was a laboratory skin model, but it showed how a pigment-producing cell could affect more than pigmentation. Victorelli et al., The EMBO Journal

Why “zombie cells” misses part of the story

The nickname makes senescent cells sound like useless cells waiting to be removed. Biology is more context-dependent.

In a mouse wound-healing experiment, senescent cells appeared early after an injury and released a growth factor that helped the wound close. Removing those cells delayed closure. This does not tell us how to choose a face serum; it tells us that senescence can have a useful role in a particular setting. Demaria et al., Developmental Cell

The distinction is between a temporary response that helps a tissue and an accumulation of cells whose activity contributes to deterioration. Researchers therefore care about the type of cell, its surroundings and the timing of an intervention. “Fewer senescent cells” is an incomplete description until we know what was measured and why.

Senomorphic and senolytic describe different actions

These terms describe the action being studied. They are not grades of peptide strength.

Early senolytic experiments tested whether disrupting the survival systems of senescent cells could selectively kill them. Different cell types responded differently, which is one reason a result in one cell population does not automatically describe every tissue. Zhu et al., Aging Cell

For a senomorphic experiment, the question is different: do the cells behave differently while remaining alive? Researchers may track secreted signals, growth-related proteins and cell survival together. Measuring only a lower marker signal would leave open whether the cells changed state or simply disappeared.

What a peptide experiment actually tests

Peptide 14, also called OS-01, offers a concrete example. In a 2023 study, researchers examined human dermal fibroblasts and skin models, including donated skin maintained outside the body. They tracked several features of senescence alongside cell numbers, rather than relying on one marker.

One experiment investigated how cells affect their neighbors. The researchers collected the liquid in which senescent fibroblasts had been growing and applied it to other fibroblasts. That liquid increased a senescence-associated staining signal in the recipient cells. Peptide treatment reduced this effect in the tested conditions.

The team also reported changes in senescence-related markers without a corresponding loss of cell numbers. Its analysis suggested that Peptide 14 could affect progression into later senescent states, helping explain its classification as senomorphic. Several authors were OneSkin employees, founders or patent inventors. These experiments explain the biological hypothesis; they are not measurements of a serum user's visible results. Zonari et al., npj Aging

A skin study answers a different question

A useful follow-up is to test the formulation on people. In a separate 12-week study involving 22 participants, one side of each person's face received an OS-01 formulation and the other received the same base formulation without the peptide. Researchers assessed skin with instruments, expert grading and participant questionnaires.

The peptide side showed a greater reduction in water loss through the skin than the control side, alongside reported advantages in appearance measures. Water loss is a measure of barrier function. A wrinkle image records appearance. Both can matter to a skincare user, but neither is a direct count of senescent cells. Zonari et al., Journal of Cosmetic Dermatology

That distinction helps you read a study without dismissing useful results or asking them to answer a question they did not test. An improvement in skin function and an explanation of its cellular cause are separate pieces of evidence.

How to use this when choosing peptide skincare

Start with the result you want to understand. For smoother-looking skin, a formulation study measuring texture is directly relevant. For a question about senescence, look for measurements of cell state or signalling. The word “peptide” alone does not connect the two.

A “peptide stack” simply describes a combination. Adding more peptides does not establish that the mixture has the same action as a particular peptide in a published experiment. Look for three details in the research a product points to:

• What was tested? An isolated ingredient, a combination or the finished formula you would use.
• Where was it tested? Cells in a dish, donated skin outside the body or people applying it to their faces.
• What changed? A biological marker, barrier function, measured appearance or a participant's assessment.

The formulation also matters: putting an ingredient on intact skin is a different exposure from adding it directly to cells in a dish. Our guide to peptide stability and skin delivery explains that next step.

If you are choosing between the specific products, continue to the Aurabiōm and OneSkin comparison. Bring one question with you: does the evidence measure the outcome I care about, in the formulation I am considering?